Alessandro Santin MD

Professor, Obstetrics & Gynecology, Yale University School of Medicine

20 York StNew Haven, CT 06510
Phone+1 203-737-4450
Fax+1 203-737-4339

Dr. Santin is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Santin's full profile Already have an account?

Summary

Dr. Alessandro Santin is a specialist in Obstetrics and Gynecology based in New Haven, CT, who joined the Yale School of Medicine faculty as full professor in 2008. He is an expert in the treatment of neoplasms affecting the ovaries, uterus, and cervix. He has multiple publications in prominent journals such as the New England Journal of Medicine, the Journal of Clinical Oncology, the Proceeding of the National Academy of Science, Clinical Cancer Research, and Gynecologic Oncology, where he has investigated topics like novel personalized treatment modalities and immunotherapy in gynecologic tumors resistant to chemotherapy. Dr. Santin has also contributed as a sponsor-investigator and principal investigator in numerous clinical trials, particularly those focusing on treatments for ovarian, uterine and cervical cancer. His recognitions include receiving the CMS Meaningful Use Certification in addition to multiple awards and being named one of America's Top Doctors by Castle Connolly from 2010 to 2026.

Education & Training

Yale School of MedicineClass of 1989

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

AR State Medical License 1998 - 2026
CT State Medical License 2007 - 2026

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017

Clinical Trials

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
COMPLETED
PHASE2
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Start of enrollment: 2015 May 18
ACTIVE_NOT_RECRUITING
PHASE2
A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
RECRUITING
PHASE2

Publications & Presentations

PubMed

Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201.
Rachel N Grisham, Els Van Nieuwenhuysen, Alessandro D Santin, Véronique D'Hondt, Premal H Thaker
Gynecologic Oncology. 2026-09-16
Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRα), and human epidermal growth factor receptor 2 (HER2) in endo...
Orazio De Tommasi, Luca Palmieri, Stefania Bellone, Natalia Buza, Namrata Sethi
Gynecologic Oncology. 2026-09-01
Whole-Exome Sequencing Identifies Candidate Genomic Features Associated with Response to Platinum-Based Chemotherapy and Ixabepilone-Based Treatment in Ovarian Cancer.
Tobias M P Hartwich, Stefania Bellone, Orazio De Tommasi, Sarah Ottum, Victoria Ettorre
International Journal of Molecular Sciences. 2026-08-22

Journal Articles

Phase II Evaluation of Nivolumab in the Treatment of Persistent or Recurrent Cervical Cancer (NCT02257528/NRG-GY002)
Alessandro D Santin, Natalia Buza, Samir Khleif, Elena S Ratner, Roisin E O'Cearbhaill, Michael Birrer, Gynecologic Oncology

Lectures

A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

Breast Cancer Drug Is Effective for Treatment-Resistant Uterine CancerMay 14th, 2026
Sacituzumab Govitecan Shows Promise in Advanced Endometrial CancerAugust 15th, 2024
Treatment for Recurrent Uterine Cancer Advances to Next Research PhaseJuly 31st, 2024

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Similar Physicians & HCPs

Christine Richter, MD
OB/GynNew Haven, CT
Amanda Rostkowski, MD
OB/GynHamden, CT
Mitchell Clark, MD
OB/GynNew Haven, CT
Olga Grechukhina, MD
OB/GynNew Haven, CT
Anna Denoble, MD
OB/GynNew Haven, CT
Christopher Arkfeld, MD
OB/GynNew Haven, CT
Melissa Markowitz, MD
OB/GynNew Haven, CT
Eun Sook Choi, MD
OB/GynNew Haven, CT
Ashley Goreshnik, MD
OB/GynNew Haven, CT
Melissa Markowitz, MD
OB/GynNew Haven, CT

Doximity / States / Connecticut / New Haven / Alessandro Santin, MD

Dr. Alessandro Santin, Dr. Alessandro Santin, MD, Dr. A Santin